Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab
Farrukh T. Awan(The University of Texas Southwestern Medical Center), David Lucas(Vital Strategies)
Cited by 69
Related Papers
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody
|Blood|2009|128
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia
|JACC CardioOncology|2023|107
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
|Journal of the National Comprehensive Cancer Network|2022|84
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
|Journal of the National Comprehensive Cancer Network|2024|83